secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2026-11-09T11:30:34+00:00
Accession:  0001493152-26-050606
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Abeona acquires Ellodi's APT-1011 (ABO-801) for $20M stock plus up to $60M milestones; raises $30M PIPE
--------------------------------------------------------------------------------

- Acquired APT-1011 (renamed ABO-801), a once-daily oral fluticasone propionate ODT for eosinophilic esophagitis; $20M paid in 4,494,383 ABEO shares, no upfront cash.
- Ellodi eligible for $30M on FDA NDA approval and up to $30M in sales milestones, plus low-to-mid-teens royalties; 4,494,383 shares locked up 1/3 at 6, 12, 18 months.
- Private placement: 6,400,000 shares at $3.75 plus pre-funded warrants for 1,600,043 shares at $3.7499, ~$30M gross; investors include Nantahala, TPG, Perceptive; Morgan Stanley agent.
- ABO-801 holds FDA Orphan Drug and Fast Track designations; two completed Phase 3 trials (361 patients) missed the co-primary symptom endpoint but showed significant endoscopic gains.
- Phase 3 trial planned to start Q2 2027, topline by end-2028; ~360,000 patients in the U.S. diagnosed with EoE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315226050606/0001493152-26-050606-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315226050606/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-050606

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer